Serious Health Complications Linked to GLP-1 Weight Loss Drugs Some GLP-1 patients in Atlanta have experienced severe side effects and health problems
Moreover, its body actions include promoting satiation, slowing gastric emptying, and changing post-meal glucagon secretion
The consolidated cases in MDL 3094 include claims involving multiple GLP-1 receptor agonist medications: Ozempic and Wegovy (semaglutide) manufactured by Novo Nordisk Rybelsus (oral semaglutide) manufactured by Novo Nordisk Mounjaro (tirzepatide) manufactured by Eli Lilly Trulicity (dulaglutide) manufactured by Eli Lilly Saxenda (liraglutide) recently added to the MDL in December 2024 Unlike a traditional class action where all plaintiffs receive identical settlements, the MDL process for Ozempic cases allows for individualized compensation based on injury severity, duration of use, and specific damages incurred
doi: 10.1186/s12964-020-00663-1 48 LongYTaoHKarachiAGrippinAJJinLChangYEet al
Caution is warranted in individuals with a history of pancreatitis or thyroid carcinoma, and close monitoring for potential cardiovascular risks is essential, particularly in high-risk populations
doi:10.1111/ced.15327 Kang, D., J
